Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LRAT | O95237 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12445645 | 1.00 | MEN1 (0.43) | MEN1LRATTRPV1HSD17B10TSHR | |
| SCHEMBL12305821 | 0.90 | MEN1 (0.38) | MEN1LRATTRPV1HSD17B10TSHR | |
| SCHEMBL14260217 | 0.89 | MEN1 (0.46) | MEN1LRATTRPV1HSD17B10TSHR | |
| SCHEMBL13245876 | 0.84 | MEN1 (0.34) | MEN1LRATTRPV1HSD17B10TSHR | |
| SCHEMBL22105653 | 0.83 | L3MBTL1 (0.43) | MEN1 | |
| SCHEMBL17929147 | 0.82 | MEN1 (0.41) | MEN1LRATTRPV1HSD17B10TSHR | |
| SCHEMBL13816267 | 0.81 | L3MBTL1 (0.38) | MEN1LRATTRPV1HSD17B10TSHR | |
| SCHEMBL24390139 | 0.79 | L3MBTL1 (0.38) | MEN1LRATTRPV1HSD17B10TSHR | |
| SCHEMBL15459181 | 0.79 | TSHR (0.55) | MEN1LRATTRPV1HSD17B10TSHR | |
| SCHEMBL22639646 | 0.77 | L3MBTL1 (0.51) | MEN1LRATTRPV1HSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911354-B2 | Substituted fatty acids for treating non-alcoholic steatohepatitis | BASF (NO) | 2024-02-27 | — | — | US | disclosed |
| US-20180110747-A1 | USE OF THIA OXO COMPOUNDS FOR LOWERING APO C3 | BASF AS (NO) | 2018-04-26 | — | — | US | disclosed |
| US-20180104201-A1 | USE OF STRUCTURALLY ENHANCED FATTY ACIDS CONTAINING SULPHUR FOR PREVENTING AND OR TREATING NON ALCOHOLIC STEATOHEPATITIS | BASF AS (NO) | 2018-04-19 | — | — | US | disclosed |
| US-20170029368-A1 | NOVEL SULPHUR CONTAINING LIPIDS FOR USE AS FOOD SUPPLEMENT OR AS MEDICAMENT | PRONOVA BIOPHARMA NORGE AS | 2017-02-02 | — | — | US | disclosed |
| US-9394228-B2 | Methods of treatment using lipid compounds | PRONOVA BIOPHARMA NORGE AS (NO) | 2016-07-19 | — | — | US | disclosed |
| US-20140316002-A1 | NOVEL SULPHUR CONTAINING LIPIDS FOR USE AS FOOD SUPPLEMENT OR AS MEDICAMENT | PRONOVA BIOPHARMA NORGE AS (NO) | 2014-10-23 | — | — | US | disclosed |
| US-20140221439-A1 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | PRONOVA BIOPHARMA NORGE AS (NO) | 2014-08-07 | — | — | US | disclosed |
| US-8759558-B2 | Sulphur containing lipids for use as food supplement or as medicament | PRONOVA BIOPHARMA NORGE AS (NO) | 2014-06-24 | — | — | US | disclosed |
| US-8741966-B2 | Lipid compounds for use in cosmetic products, as food supplement or as a medicament | PRONOVA BIOPHARMA NORGE AS (NO) | 2014-06-03 | — | — | US | disclosed |
| US-8735436-B2 | Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas | PRONOVA BIOPHARMA NORGE AS (NO) | 2014-05-27 | — | — | US | disclosed |
| US-8399516-B2 | Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (PPAR) | PRONOVA BIOPHARMA NORGE AS (NO) | 2013-03-19 | — | — | US | disclosed |
| US-20120122940-A1 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | PRONOVA BIOPHARMA NORGE AS (NO) | 2012-05-17 | — | — | US | disclosed |
| US-20110190395-A1 | NOVEL SULPHUR CONTAINING LIPIDS FOR USE AS FOOD SUPPLEMENT OR AS MEDICAMENT | PRONOVA BIOPHARMA NORGE AS (NO) | 2011-08-04 | — | — | US | disclosed |
| US-20110166228-A1 | COMPOSITION | PRONOVA BIOPHARMA NORGE AS (NO) | 2011-07-07 | — | — | US | disclosed |
| US-20100280109-A1 | LIPID COMPOUNDS FOR USE IN COSMETIC PRODUCTS, AS FOOD SUPPLEMENT OR AS A MEDICAMENT | PRONOVA BIOPHARMA NORGE AS (NO) | 2010-11-04 | — | — | US | disclosed |
| US-20100266681-A1 | FATTY ACID ALCOHOLS | PRONOVA BIOPHARMA NORGE AS (NO) | 2010-10-21 | — | — | US | disclosed |
| US-20100035990-A1 | ALPHA-SUBSTITUTED OMEGA-3 LIPIDS THAT ARE ACTIVATORS OR MODULATORS OF THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR (PPAR) | PRONOVA BIOPHARMA NORGE AS (NO) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180104201-A1 | USE OF STRUCTURALLY ENHANCED FATTY ACIDS CONTAINING SULPHUR FOR PREVENTING AND OR TREATING NON ALCOHOLIC STEATOHEPATITIS | FABP1, SLC10A1, LIPC | MEN1 4617/4885LRAT 52/4885TRPV1 3212/4885 |
| US-20110166228-A1 | COMPOSITION | ELOVL3, FFAR3, ALOX5 | MEN1 2405/4885LRAT 509/4885TRPV1 748/4885 |
| US-20100035990-A1 | ALPHA-SUBSTITUTED OMEGA-3 LIPIDS THAT ARE ACTIVATORS OR MODULATORS OF THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR (PPAR) | PPARG, PPARA, FFAR3 | MEN1 4788/4885LRAT 433/4885TRPV1 1176/4885 |
| US-20140316002-A1 | NOVEL SULPHUR CONTAINING LIPIDS FOR USE AS FOOD SUPPLEMENT OR AS MEDICAMENT | SGMS2, SGMS1, ACSS2 | MEN1 3323/4885LRAT 119/4885TRPV1 661/4885 |
| US-20170029368-A1 | NOVEL SULPHUR CONTAINING LIPIDS FOR USE AS FOOD SUPPLEMENT OR AS MEDICAMENT | SGMS2, SGMS1, FABP2 | MEN1 3148/4885LRAT 96/4885TRPV1 636/4885 |
| US-20120122940-A1 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | FFAR2, FFAR3, FFAR1 | MEN1 3961/4885LRAT 224/4885TRPV1 865/4885 |
| US-20110190395-A1 | NOVEL SULPHUR CONTAINING LIPIDS FOR USE AS FOOD SUPPLEMENT OR AS MEDICAMENT | SGMS2, SGMS1, ACSS2 | MEN1 3323/4885LRAT 119/4885TRPV1 661/4885 |
| US-20100266681-A1 | FATTY ACID ALCOHOLS | ALOX5, ALOX15, ALOX15B | MEN1 2346/4885LRAT 341/4885TRPV1 1494/4885 |
| US-20140221439-A1 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | FFAR2, FFAR3, FFAR1 | MEN1 4012/4885LRAT 233/4885TRPV1 839/4885 |
| US-20180110747-A1 | USE OF THIA OXO COMPOUNDS FOR LOWERING APO C3 | APOB, TTPA, APOL1 | MEN1 2486/4885LRAT 148/4885TRPV1 4171/4885 |
| US-11911354-B2 | Substituted fatty acids for treating non-alcoholic steatohepatitis | SLC10A1, LIPC, FABP1 | MEN1 4516/4885LRAT 51/4885TRPV1 4321/4885 |
| US-20100280109-A1 | LIPID COMPOUNDS FOR USE IN COSMETIC PRODUCTS, AS FOOD SUPPLEMENT OR AS A MEDICAMENT | SGMS1, SGMS2, C1S | MEN1 877/4885LRAT 119/4885TRPV1 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.